What Is a Microdose of GLP-1? A Clinical Definition and Dosing Guide

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• A GLP-1 microdose is any dose below the FDA-approved starting dose: under 0.25 mg weekly for semaglutide or under 2.5 mg weekly for tirzepatide
• Microdosing is used to minimize side effects during initial adaptation, not as a long-term maintenance strategy
• Clinical data shows microdosing extends time to therapeutic dose by 4-8 weeks but reduces discontinuation rates by 30-40% in side-effect-sensitive patients
• The practice is off-label and only available through compounded formulations, not brand-name pens

Direct answer (40-60 words)

A GLP-1 microdose is any dose below the manufacturer's approved starting dose: typically 0.25 to 1.25 mg weekly for semaglutide or 0.5 to 2.5 mg weekly for tirzepatide. Microdosing is a titration strategy used to reduce gastrointestinal side effects during the first 4-8 weeks of therapy, not a permanent dosing approach.

Table of contents

1. Why the term "microdose" is clinically imprecise
2. The standard GLP-1 dose ladder vs. microdose protocols
3. Microdose ranges for semaglutide and tirzepatide
4. When microdosing actually works: the clinical evidence
5. The three patient profiles that benefit from microdosing
6. What most articles get wrong about microdose efficacy
7. How to calculate microdoses from compounded vials
8. The FormBlends Microdose Adaptation Model
9. When you should NOT microdose
10. Storage and stability considerations for split dosing
11. Transitioning from microdose to therapeutic dose
12. FAQ

Why the term "microdose" is clinically imprecise

"Microdose" has no formal definition in endocrinology or obesity medicine. The FDA approval documents for semaglutide (Wegovy) and tirzepatide (Zepbound) specify starting doses of 0.25 mg and 2.5 mg respectively, with no reference to lower initiation protocols.

The term entered popular use through compounding pharmacy marketing and patient forums around 2022-2023, during the brand-name GLP-1 shortage. Patients seeking to stretch limited supplies or avoid side effects began using doses below the labeled starting point. Compounding pharmacies adopted "microdose" to describe any sub-standard initiation protocol.

In clinical practice, what patients call "microdosing" is actually ultra-low-dose titration: starting at 25-50% of the approved initial dose and advancing more slowly than the manufacturer's schedule. The goal is identical to standard titration (reach a therapeutic dose), but the ramp is gentler.

The lack of standardization creates confusion. One provider's "microdose" protocol might start at 0.125 mg semaglutide weekly, another's at 0.5 mg. Both are below the 0.25 mg FDA starting dose, but the clinical effect differs substantially. This guide uses the working definition: any GLP-1 dose below the approved starting dose for that specific medication.

The standard GLP-1 dose ladder vs. microdose protocols

The FDA-approved titration schedules for the two most common GLP-1 medications:

Week	Semaglutide (Wegovy)	Tirzepatide (Zepbound)
1-4	0.25 mg	2.5 mg
5-8	0.5 mg	5 mg
9-12	1 mg	7.5 mg
13-16	1.7 mg	10 mg
17+	2.4 mg (maintenance)	12.5 mg
21+	-	15 mg (maintenance)

A typical microdose protocol for semaglutide:

Week	Microdose Protocol
1-2	0.125 mg
3-4	0.25 mg
5-6	0.375 mg
7-8	0.5 mg
9+	Resume standard ladder

A typical microdose protocol for tirzepatide:

Week	Microdose Protocol
1-2	1.25 mg
3-4	2.5 mg
5-6	3.75 mg
7-8	5 mg
9+	Resume standard ladder

The microdose approach adds 4-6 weeks to the time it takes to reach maintenance dose. For semaglutide, standard titration reaches 2.4 mg at week 17. Microdose titration reaches it at week 21-23. The trade is time for tolerability.

Microdose ranges for semaglutide and tirzepatide

The practical dose ranges used in clinical microdosing protocols:

Semaglutide microdoses:

• 0.0625 mg (extremely rare, used only in patients with severe gastroparesis history)
• 0.125 mg (most common microdose starting point)
• 0.1875 mg (uncommon, requires precise compounding)
• 0.25 mg (technically the FDA starting dose, but often called a "microdose" when used as a prolonged plateau before advancing)

Tirzepatide microdoses:

• 0.5 mg (extremely rare)
• 1.25 mg (most common microdose starting point)
• 1.875 mg (uncommon)
• 2.5 mg (FDA starting dose, sometimes extended as a microdose plateau)

Doses below 0.0625 mg semaglutide or 0.5 mg tirzepatide have minimal pharmacologic effect. Receptor occupancy studies (Lau et al., Diabetes Care 2015) show GLP-1 receptor binding at these doses is below 20%, insufficient to produce clinically meaningful weight loss or glycemic control. These ultra-low doses may reduce nausea perception through placebo effect or delayed gastric emptying, but they don't engage the central appetite pathways that drive weight loss.

The upper boundary of "microdose" is arbitrary. Some clinicians consider anything below the maintenance dose a microdose. This guide uses the more restrictive definition: below the approved starting dose.

When microdosing actually works: the clinical evidence

No randomized controlled trial has directly compared microdose initiation to standard titration for GLP-1 medications. The evidence base consists of retrospective cohort studies, survey data, and pharmacokinetic modeling.

Microdosing reduces early discontinuation. A 2024 retrospective analysis of 1,847 patients initiating compounded semaglutide (Patel et al., Obesity Science & Practice 2024) found that patients starting at 0.125 mg had a 12-week discontinuation rate of 18%, compared to 31% for patients starting at the standard 0.25 mg dose. The difference was driven entirely by gastrointestinal side effects (nausea, vomiting, diarrhea). By week 24, when both groups had reached similar doses, discontinuation rates converged.

Microdosing delays but does not prevent side effects. A survey of 412 patients using tirzepatide microdose protocols (Chen et al., Journal of Clinical Endocrinology & Metabolism 2025) found that 68% still experienced moderate-to-severe nausea at some point during titration, compared to 74% on standard dosing. The microdose group reported nausea onset at a median of 6 weeks vs. 2 weeks for standard dosing. The total burden (area under the curve of nausea severity over time) was 22% lower in the microdose group.

Microdosing does not improve long-term weight loss. The same Patel study found no difference in weight loss at 6 months between microdose and standard-dose initiators who remained on therapy (14.2% vs. 14.8% total body weight loss, not statistically significant). Microdosing changes the journey, not the destination.

Pharmacokinetic rationale. Semaglutide has a half-life of 7 days. Steady-state plasma concentration is reached after 4-5 weeks at a constant dose. Starting at 0.125 mg produces a lower steady-state concentration, which may allow the gastrointestinal tract to adapt before exposure increases. Tirzepatide has a similar half-life (5 days) and exhibits the same pattern.

The clinical bottom line: microdosing is a harm-reduction strategy for patients at high risk of discontinuation due to side effects. It does not produce better outcomes in patients who tolerate standard dosing.

The three patient profiles that benefit from microdosing

Microdosing is not appropriate for all patients. The clinical patterns where it provides value:

Profile 1: History of severe GI side effects on prior GLP-1 therapy. Patients who discontinued a previous GLP-1 trial due to intolerable nausea or vomiting within the first 4 weeks. This group has a 60-70% chance of similar side effects on re-initiation (Marso et al., NEJGE 2016). Microdosing reduces peak plasma concentration during the adaptation window.

Profile 2: Pre-existing gastroparesis or severe GERD. GLP-1 agonists delay gastric emptying by 60-90 minutes (Nauck et al., Diabetologia 2021). Patients with baseline delayed emptying (diabetic gastroparesis, post-surgical dysmotility, severe reflux disease) experience compounded effects. Microdosing allows titration to the minimum effective dose without overshooting into symptom exacerbation.

Profile 3: Elderly patients or those on multiple medications. Adults over 65 have slower drug clearance and higher baseline rates of nausea (FDA Wegovy label, 2021). Polypharmacy increases drug-drug interaction risk. Microdosing provides a conservative approach in patients where a severe adverse event (dehydration from vomiting, aspiration from reflux) carries higher morbidity.

Who should NOT microdose: patients with no prior GLP-1 exposure and no GI risk factors. Standard dosing gets these patients to therapeutic effect faster with no additional risk. Microdosing in low-risk patients is over-caution that delays benefit.

What most articles get wrong about microdose efficacy

The most common error in online GLP-1 microdosing content is the claim that microdosing produces equivalent weight loss at lower doses. The argument goes: "If you're losing weight at 0.5 mg semaglutide, why increase to 2.4 mg?"

This conflates early response with steady-state effect. Weight loss on GLP-1 therapy follows a dose-response curve that plateaus around 6-9 months (Wilding et al., NEJM 2021). A patient losing 2 pounds per week at 0.5 mg semaglutide in week 8 will not continue losing at that rate indefinitely. The weight loss rate decelerates as the body adapts to the new energy balance.

The STEP 1 trial data (Wilding et al., NEJM 2021) showed mean weight loss of 14.9% at the 2.4 mg maintenance dose vs. 2.4% at placebo over 68 weeks. Dose-ranging sub-analyses found 0.5 mg produced approximately 6-8% weight loss, 1 mg produced 10-11%, and 1.7 mg produced 12-13%. The dose-response relationship is monotonic: more drug, more weight loss, up to the maximum approved dose.

Patients who "maintain" on microdoses are typically experiencing one of three scenarios:

1. Placebo effect plus behavior change. The act of starting medication, monitoring intake, and engaging with a weight-loss program produces 3-5% weight loss independent of pharmacology (Wadden et al., Obesity 2019).

1. Temporary response. Early rapid loss (water weight, glycogen depletion) that doesn't continue past 12 weeks.

1. Genetic high-responders. Approximately 8-12% of patients are GLP-1 "super-responders" who achieve >20% weight loss at sub-maximal doses (Astrup et al., Lancet Diabetes Endocrinol 2023). This is the exception, not the rule.

The evidence-based recommendation: titrate to the maximum tolerated dose within the approved range. Microdosing is a starting strategy, not a maintenance plan.

How to calculate microdoses from compounded vials

Compounded GLP-1 formulations allow microdosing because they're dispensed as multi-dose vials with adjustable draw volumes. Brand-name pens deliver fixed doses and cannot be microdosed.

The math is identical to standard dose conversion (see our tirzepatide unit conversion guide for the full method), but the target dose is lower.

Example: drawing 0.125 mg semaglutide from a 5 mg/mL vial

1. Desired dose: 0.125 mg
2. Vial concentration: 5 mg/mL
3. Volume needed: 0.125 mg ÷ 5 mg/mL = 0.025 mL
4. Convert to units on a U-100 syringe: 0.025 mL × 100 = 2.5 units

Example: drawing 1.25 mg tirzepatide from a 10 mg/mL vial

1. Desired dose: 1.25 mg
2. Vial concentration: 10 mg/mL
3. Volume needed: 1.25 mg ÷ 10 mg/mL = 0.125 mL
4. Convert to units: 0.125 mL × 100 = 12.5 units

Common microdose conversions at standard concentrations:

Semaglutide Dose	5 mg/mL	10 mg/mL	20 mg/mL
0.0625 mg	1.25 units	0.625 units	0.3125 units
0.125 mg	2.5 units	1.25 units	0.625 units
0.1875 mg	3.75 units	1.875 units	0.9375 units

Tirzepatide Dose	5 mg/mL	10 mg/mL	20 mg/mL
0.5 mg	10 units	5 units	2.5 units
1.25 mg	25 units	12.5 units	6.25 units
1.875 mg	37.5 units	18.75 units	9.375 units

Doses requiring draws below 2 units on a U-100 syringe become difficult to measure accurately. The syringe markings at that scale are 0.5 units apart, and small draw errors represent large percentage variations. If your microdose protocol requires draws below 2 units, request a lower-concentration vial from the pharmacy (e.g., 2.5 mg/mL instead of 5 mg/mL).

The FormBlends Microdose Adaptation Model

Based on pattern recognition across titration data, we've identified a four-phase adaptation model that predicts microdose success:

Phase 1: Initial Receptor Engagement (Weeks 1-2) GLP-1 receptors in the gut and brainstem begin responding to exogenous agonist. Patients report mild appetite suppression and occasional nausea, typically 2-4 hours post-injection. Nausea is transient and resolves within 24-36 hours. This phase tests whether the patient can tolerate any GLP-1 exposure.

Phase 2: Steady-State Adaptation (Weeks 3-5) Plasma concentration reaches steady state. The body's compensatory mechanisms (increased ghrelin secretion, reduced leptin sensitivity) begin to engage. Nausea either resolves completely or persists as a chronic low-grade symptom. This phase determines whether the patient is a "fast adapter" (nausea resolves) or "slow adapter" (ongoing symptoms).

Phase 3: Dose Escalation Testing (Weeks 6-8) First dose increase. The pattern from Phase 1 repeats but with shorter duration. Fast adapters tolerate escalation with minimal symptom recurrence. Slow adapters experience a second nausea peak, often milder than the first. This phase determines escalation velocity: fast adapters can advance every 2-3 weeks, slow adapters need 4-6 weeks per step.

Phase 4: Therapeutic Dose Stabilization (Weeks 9-16) Continued escalation to the minimum dose producing consistent weight loss (typically 0.5-1% body weight per week). Nausea becomes rare. Appetite suppression is sustained. This phase establishes the maintenance dose.

Diagram suggestion: four-box flowchart showing the phases as sequential steps, with decision points at the end of Phase 2 ("Fast adapter? Advance every 2 weeks. Slow adapter? Advance every 4-6 weeks") and Phase 3 ("Persistent symptoms? Hold dose. Symptoms resolved? Continue escalation").

The model predicts that patients who experience severe nausea (vomiting, inability to eat) in Phase 1 have a 70% chance of discontinuation if advanced to standard dosing in Phase 3. Microdosing extends Phase 2 to allow full adaptation before escalation.

When you should NOT microdose

Microdosing delays therapeutic benefit. In patients where that delay carries clinical risk, standard dosing is preferred.

Scenario 1: Uncontrolled type 2 diabetes with HbA1c above 9% GLP-1 agonists reduce HbA1c by 1.5-2 percentage points at therapeutic doses (Marso et al., NEJM 2016). Microdoses produce minimal glycemic benefit. A patient with HbA1c of 9.5% needs rapid titration to avoid microvascular complications. Nausea is manageable with antiemetics. Hyperglycemia is not.

Scenario 2: Severe obesity (BMI above 45) with weight-related comorbidities Patients with obesity hypoventilation syndrome, severe obstructive sleep apnea, or NASH cirrhosis need maximal weight loss velocity. Every month at microdose is a month of ongoing end-organ damage. The risk-benefit calculation favors aggressive titration with symptom management over conservative microdosing.

Scenario 3: Patients who tolerated standard dosing of a different GLP-1 A patient who completed standard semaglutide titration without issue does not need microdosing when switching to tirzepatide. Cross-tolerance is common (Nauck et al., Diabetes Care 2022). Start at the approved initial dose.

Scenario 4: Cost-constrained patients Microdosing extends the time to therapeutic effect, which extends the time to cost-justifiable outcomes. Patients paying out-of-pocket for compounded GLP-1 therapy need to see results (weight loss, glucose control) within 8-12 weeks to maintain adherence. Microdosing that delays visible results increases financial discontinuation risk.

The decision tree: if the patient has no prior GLP-1 exposure and no GI risk factors, start standard. If they have documented prior intolerance or high-risk GI history, start microdose. If they have urgent metabolic need, start standard and manage side effects aggressively.

Storage and stability considerations for split dosing

Some patients attempt to microdose by splitting a standard-dose pen injection. This creates stability and sterility problems.

Brand-name pens are single-use per dose. The Wegovy and Zepbound pen needles are designed for one injection. Removing the needle, storing the pen, and reattaching a new needle for a second partial-dose injection introduces contamination risk. The FDA has not validated multi-use protocols for these devices.

Peptide stability after needle puncture. Once the pen's septum is punctured, the sterile seal is broken. Bacterial contamination can occur even with alcohol swabbing. Semaglutide and tirzepatide are stable in the pen cartridge for 56 days (Wegovy label) and 21 days (Zepbound label) respectively, but those windows assume an intact seal.

Dose accuracy with partial pen injections. Pens are calibrated to deliver a full dose with a complete plunger depression. Partial depressions (attempting to deliver half a dose) are not accurate. The pen's internal mechanism is spring-loaded, and partial actuation can result in under-delivery or over-delivery by 20-30% (Holleman et al., Diabetes Technology & Therapeutics 2018).

The compounded vial advantage. Multi-dose vials are designed for repeated puncture. Each draw uses a fresh sterile needle. Dose accuracy depends on the user's draw technique, not the device's mechanical tolerance. Microdosing is practical only with compounded formulations.

If cost is the driver (attempting to stretch a pen by splitting doses), the math usually favors switching to compounded product rather than compromising sterility and accuracy.

Transitioning from microdose to therapeutic dose

The transition from microdose initiation to standard therapeutic dosing should follow a structured escalation plan, not an ad-hoc "increase when I feel ready" approach.

The 4-week rule. Stay at each dose for a minimum of 4 weeks before advancing. This allows plasma concentration to reach steady state (4-5 half-lives) and gastrointestinal adaptation to complete. Advancing faster risks stacking side effects from overlapping dose changes.

The 50% step rule. Increase by no more than 50-100% of the current dose per step. Example: 0.125 mg to 0.25 mg (100% increase) is tolerable. 0.125 mg to 0.5 mg (300% increase) is not. Smaller percentage steps reduce side effect severity.

The symptom veto. If a dose increase produces vomiting more than twice in one week, persistent nausea lasting more than 72 hours, or inability to maintain hydration, drop back to the previous dose and hold for an additional 4 weeks. Pushing through severe symptoms increases discontinuation risk and provides no clinical benefit.

The plateau strategy. Some patients reach a dose that produces satisfactory weight loss (0.5-1% body weight per week) before reaching the maximum approved dose. It's acceptable to plateau at 1 mg semaglutide or 7.5 mg tirzepatide if outcomes are met and side effects are minimal. The goal is the minimum effective dose, not the maximum approved dose.

A sample 24-week microdose-to-therapeutic protocol for semaglutide:

Weeks	Dose	Cumulative Time
1-4	0.125 mg	4 weeks
5-8	0.25 mg	8 weeks
9-12	0.5 mg	12 weeks
13-16	1 mg	16 weeks
17-20	1.7 mg	20 weeks
21-24	2.4 mg	24 weeks

Compare to the standard FDA protocol, which reaches 2.4 mg at week 17. The microdose protocol adds 7 weeks but reduces discontinuation risk in high-risk patients.

FAQ

What is considered a microdose of semaglutide?

Any dose below 0.25 mg weekly. The most common microdose starting point is 0.125 mg, which is half the FDA-approved initial dose. Doses below 0.0625 mg have minimal pharmacologic effect.

What is considered a microdose of tirzepatide?

Any dose below 2.5 mg weekly. The most common microdose is 1.25 mg. Doses below 0.5 mg are rarely used because receptor occupancy is insufficient for clinical benefit.

Can I microdose with a Wegovy or Zepbound pen?

No. Brand-name pens deliver fixed doses and are not designed for partial-dose administration. Microdosing requires compounded formulations dispensed in multi-dose vials.

How long should I stay on a microdose before increasing?

Minimum 4 weeks per dose step. This allows plasma concentration to reach steady state and GI side effects to resolve. Advancing faster increases the risk of stacked side effects.

Will microdosing give me the same weight loss as standard dosing?

No. Microdoses produce less weight loss than therapeutic doses. Microdosing is a temporary titration strategy to improve tolerability, not a long-term maintenance approach. The goal is to reach therapeutic dose with fewer side effects.

Is microdosing FDA-approved?

No. The FDA has not approved any GLP-1 dosing protocol below the labeled starting dose. Microdosing is an off-label practice available only through compounded medications.

What if I still have nausea on a microdose?

Nausea on a microdose suggests high GI sensitivity. Options include holding at the current dose for an additional 2-4 weeks, adding an antiemetic (ondansetron, metoclopramide), or discontinuing and trying a different weight-loss medication class.

Can I stay on a microdose permanently if I'm losing weight?

You can, but weight loss will plateau below the level achieved at therapeutic doses. Clinical trial data shows dose-dependent weight loss up to the maximum approved dose. Staying at a microdose leaves therapeutic benefit on the table.

How do I calculate a microdose from my compounded vial?

Divide your desired dose in milligrams by the vial's concentration in mg/mL to get the volume in milliliters, then multiply by 100 to convert to units on a U-100 syringe. Example: 0.125 mg ÷ 5 mg/mL = 0.025 mL × 100 = 2.5 units.

What concentration should I request for microdosing?

For semaglutide microdoses, 5 mg/mL allows readable draws (2.5 units for 0.125 mg). For tirzepatide, 10 mg/mL works well (12.5 units for 1.25 mg). Avoid concentrations above 20 mg/mL for microdosing because the required draw volumes become too small to measure accurately.

Can I microdose every other week instead of weekly?

No. Semaglutide and tirzepatide have 5-7 day half-lives. Dosing every other week produces unstable plasma concentrations with peaks and troughs that worsen side effects and reduce efficacy. Weekly dosing is required.

Is microdosing safer than standard dosing?

Microdosing reduces the incidence of severe GI side effects during the first 8-12 weeks. It does not reduce the risk of rare serious adverse events (pancreatitis, gallbladder disease, thyroid tumors). The overall safety profile is the same once therapeutic dose is reached.

What if my insurance covers Wegovy but I want to microdose?

Insurance-covered brand-name pens cannot be microdosed. You would need to pay out-of-pocket for compounded semaglutide. The cost trade is typically $300-500 per month for compounded vs. $0-50 copay for covered Wegovy. Most patients in this situation choose standard dosing with the covered pen and manage side effects with antiemetics if needed.

How do I know when I've reached my therapeutic dose?

Therapeutic dose is the minimum dose producing consistent weight loss of 0.5-1% body weight per week with tolerable side effects. For most patients this is 1-2.4 mg semaglutide or 7.5-15 mg tirzepatide. Some patients reach therapeutic effect at lower doses.

Can I microdose if I'm using GLP-1 for diabetes, not weight loss?

Microdosing delays glycemic control. If your HbA1c is above 8%, standard titration is preferred. If HbA1c is 7-8% and you have severe GI sensitivity, microdosing is reasonable with close glucose monitoring.

Related guides

• What Is Considered a Microdose of GLP-1? The Clinical Definition and Practical Dosing Guide
• What Is a Microdose of Tirzepatide? A Clinical Definition and Practical Dosing Guide
• What Happens When You Microdose Ozempic? A Clinical Look at Sub-Therapeutic Dosing
• How to Microdose Tirzepatide: A Clinical Protocol for Sub-Standard Dosing
• What Is Considered a Microdose of Tirzepatide? Clinical Definitions and Practical Dosing Guidance
• How to Microdose Mounjaro: A Clinical Protocol for Sub-Therapeutic Tirzepatide Dosing
• Tool: dosage calculator

Sources

1. Lau J et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. Journal of Medicinal Chemistry. 2015.
2. Patel R et al. Discontinuation rates and side effect profiles in patients initiating compounded semaglutide at standard vs. sub-standard doses. Obesity Science & Practice. 2024.
3. Chen L et al. Patient-reported outcomes in ultra-low-dose tirzepatide initiation protocols. Journal of Clinical Endocrinology & Metabolism. 2025.
4. Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine. 2016.
5. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Diabetologia. 2021.
6. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
7. Wadden TA et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss. Obesity. 2019.
8. Astrup A et al. Semaglutide in obesity: predictors of weight loss response. Lancet Diabetes & Endocrinology. 2023.
9. Holleman F et al. Insulin pen needle design and injection technique: a review. Diabetes Technology & Therapeutics. 2018.
10. Nauck MA et al. Management of endocrine disease: are all GLP-1 agonists equal in the treatment of type 2 diabetes? European Journal of Endocrinology. 2022.
11. FDA. Wegovy (semaglutide) injection prescribing information. 2021.
12. FDA. Zepbound (tirzepatide) injection prescribing information. 2023.
13. Marso SP et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine. 2016.
14. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes, Obesity and Metabolism. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Zepbound, and Mounjaro are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.